Charles
Cantor, PhD, professor emeritus at Boston University and former
principal scientist of the Human Genome Project joined the Science
Advisory Board of InSilico Medicine, Inc.
BALTIMORE, Md., June 4,
2014 (GLOBE NEWSWIRE) -- via PRWEB - InSilico Medicine, Inc. announced
today that Charles Cantor, Ph.D. will chair its Scientific Advisory
Board.
Dr. Cantor, one of
the leaders of the Human Genome Project, has published more than 400
peer-reviewed articles, authored and co-authored more than 50 U.S. and
international patents. He is also an author of the first genomics
textbook, "Genomics: The Science and Technology of the Human Genome
Project" and the three-volume textbook "Biophysical Chemistry".
"Professor
Cantor's discoveries and leadership are already helping save lives and
improve human health span. What is less known is his interest in areas
related to aging including the complex and multi-year research projects
in isotopically-fortified organic compounds and advanced diagnostics
using the cell-free nucleic acids. He is the role model for the many
research scientists aspiring to utilize resources available in the
private sector, accelerate scientific research without the many formal
constraints and budgetary limitations of academia and turn their
discoveries into practical projects. We are honored to have Charles join
our advisory board", said Alex Zhavoronkov, PhD, CEO of InSilico
Medicine, Inc.
Dr. Cantor is
the co-founder of Sequenom, Inc, a company engaged in non-invasive
prenatal diagnostics and co-founder of Retrotope, a company developing
isotopically-fortified organic compounds to bolster stress resistance
and combat age-related diseases and acts as a consultant for several
companies within the biotechnology industry. He is professor emeritus at
the Boston University, distinguished adjunct professor at the
University of California Irvine and adjunct professor at the Moscow
Institute of Physics and Technology and at Scripps Research Institute.
Dr. Cantor was previously the chair and professor of the department of
biomedical engineering and biophysics, and director of the Center for
Advanced Biotechnology at Boston University, and his research laboratory
remains active.
"Aging is
one of the most pressing problems facing the economies of the developed
countries and there is an urgent need for new ways to increase
productive longevity and screening the known drugs for their
geroprotective properties and personalizing anti-cancer and
aging-suppressive regiments using genetic and epigenetic analysis is one
of the low hanging fruits in applied aging research. I am pleased to
join the SAB of this international team dedicated to develop working
solutions for both aging and age-related diseases", said Charles Cantor,
PhD, chair of the Science Advisory Board of InSilico Medicine, Inc.
Dr.
Cantor was the chairman of Genetics and Development at Columbia
University College of Physicians & Surgeons, and Professor of
Molecular Biology, University of California, Berkeley.
He earned his bachelor's degree in chemistry at Columbia College, and his doctorate at the University of California Berkeley.
About InSilico Medicine, Inc.
Insilico
Medicine, Inc. is a Baltimore-based bioinformatics and drug discovery
company specializing in cancer and aging research and personalized
medicine in age-related diseases. The company is developing models and
softwares to predict the efficacy of the various targeted drugs in
oncology and extrapolated these methods to evaluate the possible
geroprotective properties of the many drugs with known molecular
targets. The mission of InSilico Medicine is to find working solutions
to treat, cure and prevent age-related diseases and aging itself through
excellence in knowledge management, machine learning and
bioinformatics, relentless pursuit for new drug, omics and clinical
outcomes data, development of reliable in silico drug screening methods,
novel validation approaches and strong international partnerships in
personalized medicine. This mission will be achieved within the
regulatory frameworks as well as the legal and ethical boundaries and by
working with the outstanding scientists, academic and medical
institutions and pharmaceutical companies of impeccable credibility. For
more information please visit
http://www.InSilicoMedicine.com .
Contact @ Insilico Medicine, Inc.:
InSilico Medicine, Inc.
Johns Hopkins University Eastern Campus
B301, 1101 East 33rd Street
Baltimore, MD 21218
Qinsong Zhu, PhD
Chief Operating Officer
+14107109674
zhu@insilicomedicine.com
